[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SingHealth Polyclinics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100621509","continuous-glucose-monitoring-cgm-in-prediabetes-100621509",false,"NCT07371546","Continuous Glucose Monitoring (CGM) in Prediabetes","Continuous Glucose Monitoring (CGM) in Prediabetes: A Mixed-Methods Study Exploring Behavioural Impact, Patient Experiences and Provider Perspectives","Patient Participants\n\nInclusion Criteria:\n\n1. Singaporean Citizen or Permanent Resident\n2. Age 21 - 69 years old\n3. Clinical diagnosis of prediabetes defined as a fasting glucose of 6.1-6.9 mmol\u002FL and\u002For 2-hour glucose level of 7.8-11.0 mmol\u002FL after an oral glucose tolerance test (Appropriate Care Guide, 2021)\n\n   a. Can be conservatively managed, or medically managed with metformin\n4. Owns a mobile phone that can download the Singapore FreeStyle LibreLink App\n5. Expressed willingness to use participate in the study, use the devices according to the study protocol during the study period, and to sign informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or planned pregnancy within the next six months\n2. Physical limitation that prevents the patient from engaging in physical exercise\n3. Cognitively impaired based on diagnosis of dementia or mild cognitive impairment (MCI) in the electronic health records (EHR)\n4. Not adequately proficient in English\n5. Currently enrolled in another study or program that involves weight loss or dietary modifications, or novel therapeutic drug or device\n6. Planned surgery in the next six months\n7. Not able to use smartphone or the Singapore FreeStyle LibreLink App despite coaching\n8. Any end-stage disease with life prognosis of \\\u003C 2 years\n9. Patients who are not willing or are not able to commit to the entire study program\n\nHealthcare Providers (HCP) Participants HCPs from Pasir Ris Polyclinic who self-reported to have treated adults with prediabetes will be enrolled for the interviews.","ALL","21 Years","69 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"NA","Part 1 and 2 of study (For Patient Participants) The purpose of this study is to examine if the wearing of a medical device called a continuous glucose monitor (CGM) can guide adults with prediabetes modify their behaviors and manage their health, compared to traditional health coaching. Prediabetes means the study participants have a higher-than-normal blood sugar level which is not high enough to be considered type 2 diabetes yet but will put them at risk of developing it. CGM measures glucose levels without the participants having to prick fingers and involves wearing a small sensor on the back of the arm day and night which allows viewing of glucose levels on the mobile phone with a painless 1 second scan.\n\nThis is the first time the investigators are trying to do research using CGM for adults with prediabetes. the study team want to learn how practical it is to do such a study. The study will explore if wearing of a CGM sensor makes a difference in terms of health outcomes compared to regular health coaching. It also aims to understand the users' experience with the CGM system.\n\nThis study targets to recruit 76 participants from Pasir Ris Polyclinic.\n\nPart 1 of the study uses a research method called a randomized controlled trial. Participants who consent to join will be allocated to one of two groups based on chance. Half of the participants will receive the CGM sensor in addition to health coaching. This is called the intervention group. The other half of the participants will receive health coaching alone. This is called the control group. Participants in both groups will continue regular follow-up with their own primary care physicians.\n\nThere will be 3 study touchpoints, which will mainly be at Pasir Ris Polyclinic.\n\n1. Baseline visit:\n\n   * Receive health coaching that will take 20-30 minutes.\n   * Complete questionnaires about socio-demographic details, diet and physical activity which will take 20-30 minutes.\n   * Measure weight, body mass index (BMI), and waist circumference.\n   * Past medical history and medications will be retrieved from the electronic medical records.\n   * If the participants are in the intervention group, the study team will assist them to apply the Abbott Freestyle Libre continuous glucose monitoring (CGM) sensor and link it to their smartphone. The study team will also set up the LibreLink app and Libreview account.\n2. 1-month touchpoint\n\n   * Complete follow up questionnaires to assess any changes in the diet and physical activity.\n   * This touchpoint may be conducted either face-to-face or via a phone call.\n3. 6-month touchpoint\n\n   * Complete final questionnaires about the lifestyle.\n   * Measure weight, BMI and waist circumference again\n   * Uninstall the LibreLink app and Libreview account.\n\nPart 2 of the study is an in-depth interview to understand the experiences of the participants using the Abbott Freestyle Libre CGM System. This part of the study will be conducted either during the 3rd study touchpoint or on another day (within 9 months from start of intervention). The interview will last 60 minutes and will be audio-recorded. Questions asked will be regarding the general experience using the CGM, any difficulties with following the study instructions and suggestions to improve the study.\n\nPart 3 of study for Healthcare Providers Participants (HCP):\n\nThe purpose of this study is to assess the effects of CGM on adults with prediabetes and to explore the facilitators and barriers of using CGM in prediabetes management from both patients and healthcare providers. The study aims to understand the perspectives of primary care providers on the potential benefits, challenges, and feasibility of integrating CGM into prediabetes management. The findings will help pave the way for broader integration of CGM technology into public health programs targeting specific populations at high risk of diabetes to improve health outcomes.\n\nIf the participants agree to participate, they will be invited to fill in a data collection form on the demographics, qualifications and clinical experience. This will take 20-30 minutes. The participants will be interviewed either individually or in a group with other of their colleagues from the same polyclinic. During the interview, the researcher will ask questions pertaining to their experiences with prediabetes management, knowledge of CGM and their views of the potential challenges and opportunities in the utilization of CGM by prediabetic adults. The interviews will be audio recorded. participation in the study will last approximately 60 minutes.",[27],"Pre-diabetes",[29,30,31,27],"Primary care","Continuous glucose monitoring","Behavioural change","RECRUITING","2026-01-19",{"date":35,"type":36},"2026-01-28","ACTUAL",{"date":38,"type":36},"2025-10-16",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"SingHealth Polyclinics","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100597676","developing-a-gout-action-plan-in-primary-care-setting-in-singapore-100597676","NCT07061587","Developing A Gout Action Plan in Primary Care Setting in Singapore","For patient participants:\n\nInclusion Criteria:\n\n* Adults who are 21 years old and above\n* Clinical diagnosis of gout as per ACE-EULAR 2015 criteria\n* Had at least an episode of gout exacerbation within the last 1 year\n* Able to speak and read English\n* Singapore citizens or permanent residents\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Mental disorders\n* Cognitive impairment\n* Hearing and\u002F or speech impairments\n* Pregnant\n* Known terminal illness\n* Unable to provide informed consent\n\nFor healthcare professionals:\n\nInclusion Criteria (for healthcare professionals):\n\n* Currently still in clinical practice\n* Manage gout in their clinical practice\n\nExclusion Criteria (for healthcare professionals):\n\n* Not involved in gout management in the practice\n* No longer in clinical practice",{"count":52,"type":21},72,[24],"The goal of this clinical trial is to develop a gout action plan in primary care setting in Singapore among adult patients with gout, and to learn if the gout action plan can improve gout control.\n\nThe main questions it aims to answer are:\n\n* How do we develop a gout action plan in primary care setting in Singapore?\n* What is the feasibility and estimate effectiveness of the developed gout action plan?\n* Does gout action plan reduce frequency of gout flares in patients with gout?\n\nResearchers will compare gout action plan to usual clinical care to see whether gout action plan helps in improving gout control.\n\nParticipants in intervention arm will be:\n\n* given gout action plan and follow up for a course of 6 months\n* asked to keep track of their gout symptoms\n* follow up on the number of gout flares they have.",[56,57,58],"Gout; Hyperuricemia","Gout Flare","Gout Chronic",[60,61],"Gout action plan","action plan","NOT_YET_RECRUITING","2025-07-02",{"date":65,"type":36},"2025-07-11",{"date":67,"type":21},"2025-08",{"date":69,"type":21},"2027-07",{"name":42,"class":43},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100595567","evaluation-of-osteo-buddy-in-improving-osteoporosis-knowledge-100595567","NCT07034131","Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge","Improving Both Health in Women With the Use of Osteo-Buddy to Enhance Osteoporosis Knowledge - A Mixed Method Clinical Trial","Inclusion Criteria:\n\n* Age 50 and above\n* Medium or high Osteoporosis Self-Assessment Tool for Asians (OSTA) score\n* Not undertaken Bone Mineral Density (BMD) scan\n* Never been treated with anti-osteoporosis medications such as bisphosphonates (e.g. alendronate, risendronate, ibandronate, zolendronate, pamidronate) or denosumab\n* Able to read and speak English\n* Currently use and own a smartphone where Osteo-Buddy can be used\n\nExclusion Criteria:\n\n* Known terminal illness\n* Visual, hearing and\u002For cognitive impairment or mental illness that renders them unable to provide informed consent",true,"FEMALE","50 Years",{"count":83,"type":21},80,[24],"This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.",[87,88],"Osteoporosis Risk","Osteoporosis, Postmenopausal","2025-06-26",{"date":91,"type":36},"2025-07-01",{"date":93,"type":21},"2025-07",{"date":95,"type":21},"2026-03",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":71},"100545088","remote-patient-monitoring-solution-for-chronic-respiratory-disease-management-100545088","NCT06377345","Remote Patient Monitoring Solution for Chronic Respiratory Disease Management","Inclusion Criteria:\n\n* Diagnosis of asthma\n* Pediatric patients (age 7 to 17), adult patients (age 18 and above\n* Have an asthma exacerbation on the day of visit\n* Be willing to use the AeviceMD device\n* Has a smart phone to download the application that is paired with Aevice\n* Has wireless fidelity (WIFI) connection to use with Aevice\n* English speaking\n\nExclusion Criteria:\n\n* No capacity for consent\n* Concurrent chronic obstructive pulmonary disease (COPD)","7 Years","90 Years",{"count":106,"type":21},180,[24],"Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.\n\nMethodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.\n\nImportance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation.\n\nPotential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.",[110,111,112,113,114],"Asthma","Asthma Attack","Asthma in Children","Asthma Acute","Asthma Chronic","2025-05-12",{"date":117,"type":36},"2025-05-15",{"date":119,"type":36},"2024-05-01",{"date":121,"type":21},"2025-12-30",{"name":42,"class":43},""]